Simple Summary Monoclonal antibodies represent a major therapeutic progress in multiple
myeloma during the last decade. The use of antibodies as well as antibody drug conjugates …

Mass spectrometry (MS) techniques provide a highly sensitive methodology for the
assessment and monitoring of paraproteins compared to standard electrophoretic …

Abstract Background Daratumumab, a therapeutic IgG kappa monoclonal antibody, can
cause a false positive interference on electrophoretic assays that are routinely used to …

Objectives The therapeutic monoclonal antibody (t-mAb) daratumumab, used to treat
multiple myeloma (MM) patients, interferes with routine, electrophoretic based M-protein …

Outcomes in multiple myeloma (MM) have improved dramatically in the last two decades
with the advent of novel therapies including immunomodulatory agents (IMiDs), proteasome …

Purpose: M-protein is a well-established biomarker used for multiple myeloma monitoring.
Current improvements in multiple myeloma treatment created the need to monitor minimal …

In AL amyloidosis complete response (aCR) is defined as negative serum and urine
immunofixation with normalized free light chain ratio (FLCR). However, achievement of low …

Abstract Background Plasma cell disorders (PCDs) are typically characterized by excessive
production of a single immunoglobulin, defined as a monoclonal protein (M− protein). Some …

To determine the disease status and the response to treatment for patients with multiple
myeloma, measuring serum M-protein levels is a widely used alternative to invasive …

Approval of daratumumab (DARA), an IgGk1 monoclonal antibody targeting CD38, for the
treatment of relapsed/refractory multiple myeloma as monotherapy in November 2015 …